Nextera is a drug and target discovery company offering a unique and novel approach for improved therapeutic intervention in the major disease areas autoimmunity, chronic inflammatory disorders and cancer. Our approach is to modulate the disease at the core of the escalating immune cascade translating to disease-specific treatment without compromising systemic immunity. Our strategy is to discover new targets and develop cognate drugs together with partners. We want to address complex diseases and jointly develop therapies in major indications that today seem difficult to treat. It all starts and ends with the patient – focused onto to diseased tissue and the underlying immune repertoires, Nextera brings the unique ability to decipher clinical material with the outlook of subsequent intervention.